Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents - Wikidata - awgldk - TriplyDB

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

http://www.wikidata.org/entity/Q22241419

about

Stress weakens prefrontal networks: molecular insults to higher cognition The Association of SNAP25 Gene Polymorphisms in Attention Deficit/Hyperactivity Disorder: a Systematic Review and Meta-Analysis.Association between mobile phone use and inattention in 7102 Chinese adolescents: a population-based cross-sectional study.Systematic review of the epidemiology of attention deficit hyperactivity disorder in Arab countries.Effects of norepinephrine reuptake inhibition on postural tachycardia syndrome.Association of Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorders with Mean Platelet Volume and Vitamin D.A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.Differential roles for cortical versus sub-cortical noradrenaline and modulation of impulsivity in the rat.The impact of a model-based clinical regional registry for attention-deficit hyperactivity disorder.Is high prevalence of vitamin D deficiency a correlate for attention deficit hyperactivity disorder?A Prospective Birth Cohort Study on Maternal Cholesterol Levels and Offspring Attention Deficit Hyperactivity Disorder: New Insight on Sex Differences.Pure Autonomic Failure.

P2860

Q26781227-545B2CC3-66A1-4C14-A8EF-E99B4591D585 Q30251841-DE537890-B65E-4877-9BA9-E4D683A7F2DE Q34308842-2E09F8E9-1217-47DB-8E7F-4FC2E0DF45C8 Q36504548-8E2FDCBC-53A2-4BAD-AE5D-DE07F73FACA9 Q37328820-FD201814-A644-4811-A2D9-E269C32C577F Q37726202-A6DFF8E7-ABC6-4346-9393-11EA48640C54 Q38164670-6178E5A2-117F-4464-8215-3511745DE788 Q38953668-86773CB1-CA19-4925-B0CF-A07B5CBF5A62 Q39287555-85AB60C4-A772-41FA-B489-02FADA11448D Q39905721-0061BF96-EEDA-4D60-B33F-4512DC3DC68A Q43899035-1A6F475F-1677-4476-9862-D3C87327482B Q47218658-76B41D98-6C80-499B-A5B9-F761B7E02802 Q51685133-F4689908-7569-4063-A737-60FB709407EA

P2860

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

http://www.wikidata.org/entity/Q22241419

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@ast

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en-gb

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@nl

type

label

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@ast

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en-gb

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@nl

altLabel

Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents

@en

prefLabel

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@ast

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en-gb

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@nl

P1433

Q22241419-E3DC9950-2F19-4583-A776-90E26BF49009

P1476

Q22241419-C5428388-4747-4D29-9171-1432813336D7

P2093

Q22241419-56D14B24-0D92-41B9-8B16-751325278FBB

Q22241419-AE60EA5C-8558-469F-AAB5-2A7414BCBCCD

P2860

Q22241419-005EFA9B-3777-4DBB-BACA-3531FE986B1E

Q22241419-06A66230-78F5-4836-8839-860AEA9A9DB6

Q22241419-076279A7-027B-4033-90D0-3166FE1EDADB

Q22241419-0856B18C-B5A9-4208-9999-257893A6436C

Q22241419-0B88C236-FDA5-47E6-A13C-2276E19046CF

Q22241419-0D794E5F-E11E-458E-B042-1D98C98A81FD

Q22241419-10D43CFA-B937-4918-9266-1CEC68FEB533

Q22241419-11A06DA2-0808-42FD-81B6-FB35F08364A1

Q22241419-11A487C0-6C4D-4BFA-87C3-2C87FC300D61

Q22241419-2251BF74-02C1-4C53-A044-754C4757D62C

P2888

Q22241419-566003CE-4C63-48D6-A7A3-69878608260D

P304

Q22241419-1E9B1E1E-345B-466E-90E6-EB75C203FB1F

P31

Q22241419-A16D5049-78C6-475C-AA8F-B67242D2EDE2

P356

Q22241419-095C6EF8-14F1-4FDC-B07A-C6DF3D8FBBDA

P407

Q22241419-FC363BFC-934A-4C73-B9D2-698BEF1DC838

P433

Q22241419-36FCD81D-B27E-43AF-84DE-7FE002101BEB

P478

Q22241419-AF3E19AB-A373-400C-9F59-174EE26507BD

P577

Q22241419-82EEC53C-3DBB-415B-8EE2-27A6AF648B2F

P6179

Q22241419-A3A2A34A-6490-4C15-83D4-84FA77D7AFD3

P698

Q22241419-B094F0CA-03EA-4828-AA07-089ABB7A8059

P921

Q22241419-2C343B45-68FB-421F-B568-6D56080E2A35

Q22241419-471DF4B2-B85C-4818-9957-E0EA4C2EE476

Q22241419-C94408DF-C9AA-4FBD-9E57-520BCFE470B9

Q22241419-D55CD76F-61CE-4D41-AD57-5D42062A0718

P356

11599580-000000000-00000

P1433

P1476

Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents

@en

P2093

Ann C. Childress

http://www.w3.org/2001/XMLSchema#string

Sally A. Berry

http://www.w3.org/2001/XMLSchema#string

P2860

The MTA at 8 Years: Prospective Follow-up of Children Treated for Combined-Type ADHD in a Multisite Study

Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication--Adolescent Supplement (NCS-A)

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders

Road trauma in teenage male youth with childhood disruptive behavior disorders: a population based analysis

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data.

The longitudinal course of comorbid oppositional defiant disorder in girls with attention-deficit/hyperactivity disorder: findings from a controlled 5-year prospective longitudinal follow-up study.

A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).

Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine

Psychiatric disorders and sexual risk among adolescents in mental health treatment.

P2888

11599580-000000000-00000

P304

309-325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11599580-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1050616713

http://www.w3.org/2001/XMLSchema#string

P698

22316347

http://www.w3.org/2001/XMLSchema#string

P921

attention deficit hyperactivity disorder

pharmacotherapy